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Identity 
Other names: MRP (multidrug resistance-
associated protein) 
HGNC (Hugo): ABCC1 
Location: 16p13.1 
Note: MRP is a gene involved in multidrug 
resistance, discovered in a multidrug-resistant, P-
glycoprotein negative, non small cell lung 
carcinoma cell line. 
DNA/RNA 
Description 
Spans at least 200 kb and contains 31 exons 
Transcription 
7 kb mRNA transcript; significant level of variant 
transcripts due to alternative splicing. 
Protein 
Description 
1531 amino acids, 190 kDa; contains two ATP 
binding domains and three membrane-spanning 
helices; member of the ATP-binding cassette 
proteins (ABC proteins). 
Expression 
Expressed at a basal level in a wide variety of 
normal tissues, including epithelial cells and all 
hematopoietic cell types, which suggests a function 
common to most cell types; increased expression in 
various tumor cell type. 
Localisation 
In normal cells, predominant localisation in the 
cytoplasm; in tumor cells, predominant in plasma 
membrane, but also found in endoplasmic 
reticulum, indicating a probable different function 
as in normal cells. 
Function 
Plasma membrane drug-efflux pump; MRP induces 
a multidrug resistance phenotype (MDR 
phenotype); overexpression confers tumor cell 
resistance to a wide variety of hydrophobic drugs: 
doxorubicin, daunorubicin, vinblastine, vincristine, 
colchicine, VP16, Rhodamin 123; glutathione is 
required for the effective expulsion of the 
chemotherapeutic agents; the mode of action of 
MRP is very similar to the one of P-glycoprotein, 
the main protein responsible for the MDR 
phenotype; however, MRP does not confer 
resistance to Taxol or m-AMSA, but it is able to 
transport metallic oxyanions, glutathione and other 
glutathione conjugates; inhibitors of organic anion 
transport, such as probenecid, can block MRP 
activity. 
Homology 
Structural and/or functional homology with other 
ABC transporter proteins (CFTR, Pgp, MOAT). 
Implicated in 














In a wide variety of solid and hematological 
tumors. 
Oncogenesis 
MRP hyperexpression may confer therapeutic 
resistance in leukemia and solid tumor; however its 
relative importance, in comparison with other 
proteins able to induce the MDR phenotype (P-gp, 
LRP), is not yet clear; hyperexpression is probably 
linked to transcriptional activation of the gene 
and/or increased mRNA stability, and not to gene 
amplification; increased expression of MRP mRNA 
and protein is a factor of bad prognostic in 
neuroblastoma, retinoblastoma, and non small cell 
lung carcinoma. In haematological malignancies, 
overexpression is frequent in chronic lymphocytic 
leukemia and prolymphocytic leukemia, occasional 
in acute myeloid leukemia and rare in acute 
lymphoid leukemia, lymphoma, multiple myeloma 
and myeloproliferative disorders. 
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